Canopy Growth (TSE:WEED – Get Free Report) has been given a C$10.00 target price by equities researchers at ATB Capital in a report released on Tuesday, BayStreet.CA reports. The brokerage presently has a “sector perform” rating on the stock. ATB Capital’s price target points to a potential upside of 2.56% from the stock’s previous close.
Several other research firms have also commented on WEED. Jefferies Financial Group raised their price target on shares of Canopy Growth from C$4.90 to C$10.63 and gave the company a “hold” rating in a report on Tuesday, June 11th. CIBC cut their price target on shares of Canopy Growth from C$4.50 to C$4.00 and set an “underperform” rating on the stock in a report on Friday, May 31st. Finally, Alliance Global Partners raised their price target on shares of Canopy Growth from C$6.00 to C$11.00 in a report on Tuesday, June 4th. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of C$6.88.
Read Our Latest Analysis on Canopy Growth
Canopy Growth Trading Up 0.1 %
Insider Buying and Selling at Canopy Growth
In other Canopy Growth news, Director Willy Kruh sold 3,738 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$9.94, for a total value of C$37,155.72. 0.27% of the stock is owned by corporate insiders.
Canopy Growth Company Profile
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names.
Featured Stories
- Five stocks we like better than Canopy Growth
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- How to Invest in Insurance Companies: A GuideĀ
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- How to Invest in Biotech Stocks
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.